No description available.

Myocardial infarction (MI) is a leading cause of death in the United States, claiming the lives of approximately 500,000 people each year. The infarcted heart undergoes a compensatory process called cardiac remodeling, which adversely changes left ventricular (LV) size and function and eventually may lead to heart failure. To date, the only clinical treatments for this condition include surgical restoration of blood flow to the ischemic region (e.g., angioplasty), or pharmacological treatments (e.g., angiotensin converting enzyme inhibitors) which indirectly manage the symptoms of cardiac remodeling. Reperfusion of ischemic heart tissue significantly limits myocardial damage after an MI; however, many MI patients are not candidates for traditional reperfusion surgery. Recently, there has been much interest in non-surgical myocardial reperfusion via pro-angiogenic compounds, specifically vascular endothelial growth factor (VEGF). Although animal studies using therapeutic VEGF have shown promising results, these results have failed to translate into successful clinical trials. This may be due to the short half-life of VEGF in circulation. Increasing the dose of VEGF may increase its availability to the target tissue, but harmful side-effects remain a concert. Encapsulating VEGF and selectively targeting it to the MI border zone may improve vascularization, cardiac function, reduce adverse remodeling associated with MI, and may avoid harmful side effects associated with systemic delivery. Anti-P-selectin conjugated immunoliposomes containing VEGF were developed to target the P-selectin ligand overexpressed in the infarct border zone in a rat MI model. Serial echocardiography and Doppler imaging were used to characterize evolutionary changes in LV geometry and function over a period of four weeks after MI. At four weeks, hearts were excised and stained to measure vascularization and collagen deposition. Targeted VEGF treatment resulted in significant improvements in fractional shortening at four weeks post-infarction (32.9 ± 2.2% for targeted VEGF treated vs. 16.9 ± 1.4% for untreated MI). Functional improvements in treated MI hearts were accompanied by a 74% increase in perfused vessels in the MI border zone, compared to untreated MI hearts. Left ventricular filling dynamics were significantly improved in the targeted VEGF treated group, which resulted in a decrease in LV end diastolic pressure in VEGF treated hearts (23.4 ± 2.9 mm Hg), compared to untreated MIs (81.8 ± 31.8 mm Hg). At four weeks after infarction, hearts treated with targeted VEGF therapy exhibited a 37% reduction in collagen deposition, compared to untreated MI hearts. Targeted VEGF therapy significantly improves vascularization, cardiac function, and moderates adverse cardiac remodeling after an infarction. / Mechanical Engineering

The purpose of the current study was to test the hypothesis that chronic hypoxia associated with sleep-disordered breathing relates to abnormal Nitric Oxide (NO) production and vascular endothelial growth factor (VEGF) expression patterns that contribute to aberrancy of specific determinates of cardiovascular and cardiopulmonary function before, during, and after graded exercise. These patterns may further reflect pathologic alteration of signaling within the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt-1) transduction network. To this end, 7 medically diagnosed OSA patients (3 male, 4 female), mean age 48 years and 7 apparently healthy control subjects (3 male, 4 female), mean age 42 years, underwent baseline venous blood draws and maximal bicycle ergometry. Mononuclear cells isolated from peripheral blood were utilized as reporter cells for measurement of VEGF, Akt-1, hypoxia inducible factor-1 alpha (HIF-1 alpha), and vascular endothelial growth factor receptor-2 (VEGFR2) gene expression by redundant oligonucleotide DNA microarray and real-time PCR technologies. Circulating angiogenic progenitor cells expressing VEGFR2 were profiled by flow cytometry. Plasma and serum concentrations of VEGF, nitrates/nitrites, catecholamines, and dopamine were measured by enzyme-linked immunosorbent assay (ELISA) and high performance liquid chromatography (HPLC). Arterial blood pressure, cardiac output, oxygen consumption and total peripheral resistance were determined at Baseline, 100W, and peak ergometric stress by standard techniques. There were no apparent differences (p < .05) observed in biochemical markers relating to vascular function and adaptation including, serum nitrates/nitrites, norepinephrine, dopamine, and plasma VEGF. No differences were found relative to cardiac output, stroke volume, cardiopulmonary or myocardial oxygen consumption, expired ventilation, heart rate, arteriovenous oxygen difference, total peripheral resistance, and mean arterial pressure. Due to methodological issues related to the redundant oligonucleotide DNA microarray and real-time PCR gene expression analyses, results of these experiments were uninterpretable. Thus, the research hypothesis was rejected. Conversely, significant (p < .05) differences were observed in waist: hip ratios, recovery: peak systolic blood pressure ratio at 1 minute post-exercise and %VEGFR2 expression. OSA was associated with elevations in both waist: hip ratios and recovery: peak systolic blood pressure ratio at 1 minute post-exercise as well as significant depression of %VEGFR2 profiles. Moreover, significant negative correlations were found regarding waist: hip ratios and %VEGFR2 expression (r = -.69;p =.005) and recovery: peak systolic blood pressure ratio at 1 minute post-exercise and %VEGFR2 expression (r = -.65;p =.01). These findings did not provide evidence that NO-dependent vasoactive mechanisms are suppressed nor did they support the supposition that angiogenic mechanisms are pathologically activated in sleep-disordered breathing. / Ph. D.

Vascular endothelial growth factor (VEGF) is a potent angiogenic agent. VEGF activates its biologic responses through two cell-surface receptors, Flt1 and Flk1. In addition to the transmembrane form of Flt1, the Flt1 gene also encodes a secreted, truncated form of the receptor (sFlt1) translated from an mRNA in which a portion of intron 13 is preserved. sFlt1 retains high affinity for VEGF and thereby inhibits its angiogenic activity. Intron 13 contains important cis elements involved in sFlt1 mRNA formation. Here, we test the hypothesis that polymorphisms in the human Flt1 gene, particularly SNPs at sites suspected to contain splicing or cleavage-polyadenylation signals, influence Flt1 pre-mRNA processing and rates of Flt1 and sFlt1 expression. The NCBI SNP database contained 23 SNPs in the region of interest, one each in exons 13 and 14. An independent human SNP screen confirmed several of the reported SNPs. The web-based ESEfinder software predicted that the exon 13/14 SNPs had reduced potential for recruitment of splicing components. To test effects of exonic SNPs on Flt1 pre-mRNA processing, wild type and mutant Flt1 minigene plasmids were transfected into NIH/3T3 cells. Both exonic SNPs were associated with ~40% decreases in Flt1:sFlt1 mRNA ratios determined by real-time PCR. To facilitate exploration of ESEs in regulated RNA splicing, a PERL computer program, "EXONerator" was written to silence predicted ESEs without altering polypeptide sequence. These results support the notion that small changes in exon composition can have significant effects on splicing activity and underscore the utility of software tools for hypothesis generation. / Ph. D.

Throughout gestation, the blood vessel network of the placenta is formed sequentially by processes known as vasculogenesis and angiogenesis, which together meet the needs of the growing fetus. Normal placental angiogenesis is critical to support adequate fetal growth and assure the health of the offspring. Proper angiogenesis requires precise regulation of expression of agents that modulate this process; otherwise, pathologies of pregnancy such as preeclampsia may occur. The placenta is composed of different layers of tissue, including the lamellar (LZ), junctional, and glandular zones, each with a vascular morphology attuned to its function. We hypothesized that higher expression of pro-angiogenic factors is associated with increased morphological metrics in the LZ, the major vascularized zone. Thus, we aimed to characterize the major changes in morphology and vascular development in the placenta throughout pregnancy in cats, alongside a compressive analysis of the expression of major angiogenic factors and their receptors in the placenta, with an emphasis on the identification and interaction of different isoforms of the VEGF family. Microscopic analysis of tissue specimens from different stages of pregnancy revealed increased thickness of the LZ, especially during early to mid-gestation, at which time the tissue is composed of abundant materno-fetal interdigitations that appears rich in capillaries. VEGF proteins were detected in placental tissue in both fetal and maternal cells of the placenta, suggesting stimulatory interactions between different cell types to promote growth and angiogenesis. Gene expression analysis of placenta revealed upregulation of the pro-angiogenic factor VEGF-A in mid-pregnancy, followed by a steady decline toward term, consistent with morphologic changes in the LZ. In contrast, another pro-angiogenic factor, PlGF, showed a marked increase toward term; Flt-1, which acts as a receptor or reservoir for PLGF and VEGF A, was also upregulated at late pregnancy. Increased ratios of PLGF:VEGF-A may contribute to LZ proliferation in the last trimester. These findings are consistent with the creation of a proangiogenic placental state during gestation. Overall, we expect that this research will help elucidate mechanisms of placental vascularization, which can be applied to the design of improved strategies to treat vascular complications of pregnancy. Lastly, we applied the tools developed for placental studies to investigate pathologic angiogenesis in cutaneous squamous cell carcinoma (CSCC), a common skin cancer with major economic and medical impacts in humans and veterinary species. The creation of a new blood supply is essential for growth and metastasis of many tumor types. The goal of this study was to measure expression of variants of proteins that stimulate angiogenesis or transmit an angiogenic stimulus in feline CSCC. The results were mixed, with differences detected in expression of some regulatory agents and, for others, unexpectedly lower expression in CSSC compared to controls. Interestingly, the expression of VEGF-A relative to the protein that transmits its signal (KDR) was elevated in CSCC, suggestive of an altered signaling relationship. This finding supports our hypothesis and is consistent with human SCC studies. Our results encourage further studies on angiogenic factor variants in feline CSCC. / PHD

Angiogenesis is the formation of new blood vessels from existing vasculature. Vascular Endothelial Growth Factor (VEGF), a known angiogenic protein, stimulates endothelial cell proliferation and migration via interactions with its receptors, KDR and Flt-1. A secreted form of Flt-1 (sFlt-1), derived from alternatively-spliced RNA, can inhibit actions of VEGF in vivo. It has been suggested that alterations in sFlt-1 expression could significantly change the angiogenic VEGF activity. This project focuses on characterizing intronic elements that regulate Flt-1 mRNA splicing. A "wild-type" construct (pFIN13), containing the first 13 exons, intron 13 and exons 14-30 of mouse Flt-1, was shown to produce both forms of Flt-1 mRNA after transfection into HEK293 cells. To gauge the strength of the native splicing signals in intron 13 of Flt-1, a series of point mutations were made in the polypyrimidine tract using pFIN13. After transient transfection, the levels of Flt-1 and sFlt-1 protein and mRNA were compared using quantitative PCR, RNA hybridization analysis, and protein immunoblotting. Results from quantitative PCR showed that purine substitutions were associated with 120 to 350 fold decreases in Flt-1 mRNA (normalized against neor), consistent with less efficient splicing. These large decreases in Flt-1 mRNA were accompanied by increases in sFlt-1 mRNA. Modest (20 to 100%) increases in Flt-1 mRNA, reflecting improved splicing, resulted from increasing the uridine complement in the polypyrimidine tract. These results suggest that the wild-type polypyrimidine tract is of intermediate strength and may be a regulatory locus for modulating Flt-1: sFlt-1 ratios. / Master of Science

Damage to the vasculature is a common occurrence in diabetes mellitus. At the cellular level, dysfunction of vascular endothelial cells is often associated with diabetic conditions. Multiple agents maintain the endothelium, including vascular endothelial growth factor (VEGF), an endothelial cell mitogen/survival factor, and insulin, which has anti-apoptotic effects on endothelial cells in addition to regulating glucose homeostasis. Insulin and VEGF, upon activating their respective tyrosine kinase receptors, can engage the PI3-kinase/Akt, MAPK, and PLC-γ/PKC pathways. Thus, crosstalk between VEGF and insulin signaling may occur at numerous points. Our objectives were twofold: 1) to characterize the combined effects of insulin and VEGF on downstream elements, and 2) to determine the ability of signaling intermediates principally associated with either insulin or VEGF signaling to interact directly. After treatment with VEGF, insulin, or both, cells expressing both VEGF receptor-2 (KDR) and the insulin receptor were immunoprecipitated for total Akt and PLC-γ. Isolates from cells stimulated with both ligands demonstrated activation of PLC-γ and Akt that was less than additive over fifteen minutes. Conversely, cells pretreated with advanced glycation end products showed increased Akt phosphorylation. The effect of insulin on VEGF bioactivity was also measured by PLC-γ-mediated hydrolysis of phosphatidylinositol. These studies suggested suppressed VEGF activity in the presence of insulin. To examine direct signaling interactions, recombinant reagents capable of selective binding (via SH2 domains) to phosphorylated receptors were generated. Overall results showed relatively unaffected VEGF activity in the presence of insulin; however, this relationship is likely altered within the diabetic state. / Master of Science

Danos teciduais de qualquer natureza desencadeiam uma série de eventos que irão promover a regeneração ou a cicatrização do tecido lesado. Este reparo é um processo complexo que envolve a interação de diversos tipos celulares que são ativados por uma vasta gama de mediadores químicos, componentes da matriz extracelular, microorganismos e alterações físico químicas no microambiente da lesão e das áreas adjacentes. A participação do fator de crescimento endotelial vascular (VEGF) e de seus dois principais receptores (VEGFR-1 e -2) é de grande importância nos processos de cicatrização levando-se em conta a neovascularização. Após uma análise circunstanciada da literatura sobre os efeitos da radioterapia na neovascularização e a relação com a expressão do VEGF e VEGFR-1 e -2 na cicatrização observou-se que ainda há uma série de questões a serem investigadas. O objetivo desse projeto de pesquisa é estudar a expressão imuno-histoquímica do VEGF e VEGFR-1 e -2 e a densidade vascular sanguínea (DVS) após incisão e reparação cutânea em animais sob influência da radioterapia e em um período de aproximadamente seis meses. Neste estudo foram utilizados 60 ratos da linhagem Wistar distribuídos aleatoriamente em seis grupos (controle 3 e 6 meses, radioterapia pré-cirúrgica 3 e 6 meses, radioterapia pós-cirúrgica 3 e 6 meses). Após a eutanásia dos animais de acordo com os princípios bioéticos, foram retirados os espécimes alvo que foram avaliados macro e microscopicamente. O estudo imuno-histoquímico dos VEGFs foram realizados usando os anticorpos específicos supracitados nas diluições especificadas pelo fabricante, enquanto o estudo do DVS foi realizado com o anticorpo Von Willebrand Factor (VWF) que foi utilizado para marcar especificamente as células endoteliais. Nos períodos de tempo estudados, evidenciou-se a expressão significativa destes fatores de crescimento no tecido, na maioria dos casos. Os casos primeiramente irradiados apresentaram celularidade bizarra, com células gigantes e multinucleadas, estruturas do estroma hialinizadas e necrose imunomarcadas de moderada a forte para receptores de VEGF no endotélio e vasos sanguíneos. Essas características são consistentes com a literatura, uma vez que a forte relação do VEGFR-2 e a sua persistência na neovascularização e formação de tecido de granulação foram evidenciados. Os resultados mostraram que a expressão de VEGF é constantemente expressa em diferentes tempos da cicatrização de feridas e formação de cicatriz / Tissue damages of any nature unchain a series of events that will promote regeneration or healing of the injured tissue. This repair is a complex process that involves the interaction of various cells types. These cells are activated by a vast gamma of chemical mediators of the extracellular matrix, microorganisms and chemical and physical alterations in the injury microenvironment and adjacent areas. The participation of vascular endothelial growth factors (VEGF) and their two main receptors (VEGFR-1 and -2) has great importance in the healing process considering neovascularization. After a detailed analysis of the literature about radiotherapy effect in neovascularization and its relation with the expression of VEGF and VEGFR-1 and -2 in the healing, it was observed that there are many questions to be investigated. The objective of this study was to evaluate the immunohistochemical expression of VEGF and VEGFR-1 and -2 and sanguineous vessel density (DVS) after incision and cutaneous repairing in animals under influence of the radiotherapy at three and six months. This study used 60 Wistar rats randomly distributed in six groups: control, preoperative radiotherapy and postoperative radiotherapy, of 3 and 6 month each. The specimens evaluated macro/microscopically were removed after animal\'s sacrifice, in accordance to clinical ethics principles. The immunohistochemistry study of VEGFs were conducted using above-mentioned specific antibodies in manufacturer specified dilutions, while the study of the DVS was performed with the Von Willebrand Factor antibody (VWF) which was used to mark endothelial cells specifically. In both periods studied, surgical wound and radiation damages are similar in most cases. The primarily irradiated cases presented bizarre cellularity, multinucleated giant cells, stromal hyalinization structures, moderate to strong necrosis, overexpression of VEGF receptors in the endothelium and blood vessels in consequence of radiotherapy. These findings are in accordance to the literature, since the strong relationship between VEGFR-2 receptor and its persistence in neovascularization and granulation tissue formation were seen. Our results have shown that VEGF expression is constantly expressed in different times of wound healing and scar formation

La maladie d’Alzheimer est caractérisée par un déclin progressif des capacités cognitives. Les Aßo induisent des dysfonctionnements de la transmission via une altération des récepteurs au glutamate et une perte de synapses.Nos récents résultats démontrent que le VEGF facilite la plasticité synaptique et la mémoire chez des souris via son action sur son récepteur VEGFR2. Nous avons montré que le VEGF stimule l’insertion synaptique des récepteurs glutamatergiques et la formation de synapses, suggérant ainsi un rôle dans la modulation des altérations synaptiques observées dans la maladie d’Alzheimer.Notre objectif est d’étudier le rôle du VEGF, spécifiquement dans la maladie d’Alzheimer. Tout d’abord, nous avons examiné son expression en relation avec les plaques séniles chez des patients et dans un modèle de la maladie d’Alzheimer. Nos résultats ont démontré une colocalisation entre le VEGF et ces plaques.Afin d’examiner plus finement l’interaction Aß-VEGF, nous avons analysé la liaison entre les Aßo et le VEGF en test ELISA et puces à peptides. Nous avons ainsi démontré un potentiel blocage de l’interaction entre le VEGF et son récepteur, menant à des défauts de son activation.Enfin, nous avons examiné si le VEGF prévient les altérations synaptiques par des approches électrophysiologiques, biochimiques et immunocytochimiques. Nos résultats démontrent que lors d’un traitement aux Aßo, le VEGF restaure la LTP, l’expression des récepteurs au glutamate et limite la perte synaptique.Dans l’ensemble, nos résultats suggèrent que l’interaction Aß-VEGF altère la voie du VEGF chez les patients. De plus, le VEGF réduit la toxicité induite par les Aßo sur les synapses / Alzheimer disease (AD) is characterized by a progressive decline in cognitive abilities. Amyloid-ß oligomers (Aßo) trigger synapse dysfunction through defects in glutamate receptor function and subsequent dendritic spine loss. These synaptic impairments compromise memory and contribute to cognitive deficits.Our recent findings revealed that VEGF facilitates synaptic plasticity and memory in mice through its VEGFR2 receptor in neurons. We showed that VEGF promotes glutamate receptor synaptic insertion and stimulates dendritic spine formation, suggesting it may be a key candidate for alleviating synapse damage in AD.Our objective is to study the role of VEGF in synapse protection in AD models and unravel the underlying mechanisms.First, we examined the VEGF expression pattern in postmortem brain tissue from AD patients and APPPS1 model of AD. Our results showed a partial colocalization between VEGF and Aß plaques in AD patients and APPPS1 brains.To further investigate the Aß-VEGF interaction, we used Elisa assay and peptide arrays and demonstrated that Aßo binds several domains of VEGF, impedding VEGFR2 activation.Finally, we examined whether VEGF can prevent synapse damage induced by Aßo using electrophysiological, biochemical and 3D modelling approaches. Our results demonstrated that VEGF treatments can restore LTP in Aßo-treated hippocampal slices, glutamate receptor content at synapses and increase dendritic spine density.All together, our results suggest that Aß-VEGF interaction may alter VEGF pathway in AD and that VEGF reduces Aßo-induced toxicity at synapses by modulating glutamate receptor expression and promoting spine formation and/or stabilization

Doctor of Philosophy(PhD) / Owing to its strategic position in the liver sinusoid, pathologic and morphologic alterations of the Liver Sinusoidal Endothelial Cell (LSEC) have far-reaching repercussions for the whole liver and systemic metabolism. LSECs are perforated with fenestrations, which are pores that facilitate the transfer of lipoproteins and macromolecules between blood and hepatocytes. Loss of LSEC porosity is termed defenestration, which can result from loss of fenestrations and/ or decreases in fenestration diameter. Gram negative bacterial endotoxin (Lipopolysaccharide, LPS) has marked effects on LSEC morphology, including induction LSEC defenestration. Sepsis is associated with hyperlipidemia, and proposed mechanisms include inhibition of tissue lipoprotein lipase and increased triglyceride production by the liver. The LSEC has an increasingly recognized role in hyperlipidemia. Conditions associated with reduced numbers of fenestrations such as ageing and bacterial infections are associated with impaired lipoprotein and chylomicron remnant uptake by the liver and consequent hyperlipidemia. Given the role of the LSEC in liver allograft rejection and hyperlipidemia, changes in the LSEC induced by LPS may have significant clinical implications. In this thesis, the following major hypotheses are explored: 1. The Pseudomonas aeruginosa toxin pyocyanin induces defenestration of the LSEC both in vitro and in vivo 2. The effects of pyocyanin on the LSEC are mediated by oxidative stress 3. Defenestration induced by old age and poloxamer 407 causes intrahepatocytic hypoxia and upregulation of hypoxia-related responses 4. Defenestration of the LSEC seen in old age can be exacerbated by diabetes mellitus and prevented or ameliorated by caloric restriction commencing early in life